Atossa Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report), retaining the price target of $4.00.

Jason McCarthy has given his Buy rating due to a combination of factors surrounding Atossa Therapeutics’ strategic focus and promising clinical developments. The company is advancing its endoxifen program into metastatic breast cancer, which could potentially streamline regulatory approval processes. This move is supported by encouraging early clinical data that show significant efficacy in extending progression-free survival in certain patient groups.
Furthermore, Atossa’s ongoing clinical trials, such as the EVANGELINE and KARISMA-Endoxifen studies, have demonstrated positive results in tumor suppression and breast density reduction, respectively. The company’s robust intellectual property portfolio, with new patents granted, strengthens its competitive position. Additionally, the financial outlook is supported by a substantial cash reserve, providing a runway into 2027, and a valuation model that anticipates a commercial launch in 2028, contributing to a favorable long-term growth perspective.

According to TipRanks, McCarthy is an analyst with an average return of -21.7% and a 26.41% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Actinium Pharmaceuticals, and Gain Therapeutics.

In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.